Matinas BioPharma Holdings (MTNB) Research & Development (2013 - 2025)
Matinas BioPharma Holdings (MTNB) posted quarterly Research & Development of $85000.0 for Q1 2025, down 97.53% year-over-year from $3.4 million in Q1 2024, and down 96.42% quarter-over-quarter from $2.4 million in Q4 2024.
Matinas BioPharma Holdings (MTNB) Research & Development (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Research & Development for 13 consecutive years, with $85000.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Research & Development fell 97.53% year-over-year to $85000.0; the TTM figure through Dec 2025 stood at $85000.0 (down 99.26% YoY), while the FY2025 annual figure was $85000.0, down 99.26% from the prior year.
- Research & Development eased to $85000.0 in Q1 2025 per MTNB's latest filing, from $2.4 million in the prior quarter.
- Across five years, Research & Development topped out at $5.0 million in Q1 2022 and bottomed at $85000.0 in Q1 2025.
- Historically, Research & Development has averaged $3.4 million across 5 years, with a median of $3.6 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development soared 66.36% — and 2025, when it plunged 97.53%.
- Matinas BioPharma Holdings' Research & Development stood at $4.2 million in 2021, then dropped by 8.79% to $3.9 million in 2022, then fell by 5.22% to $3.7 million in 2023, then sank by 35.17% to $2.4 million in 2024, then plunged by 96.42% to $85000.0 in 2025.
- Business Quant data shows MTNB's Research & Development at $85000.0 in Q1 2025, $2.4 million in Q4 2024, and $2.2 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 85,000.00 |
| Dec 31, 2024 | 2.38 Mn |
| Sep 30, 2024 | 2.24 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 3.45 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 3.56 Mn |
| Mar 31, 2023 | 3.97 Mn |
| Dec 31, 2022 | 3.87 Mn |
| Sep 30, 2022 | 3.71 Mn |
| Jun 30, 2022 | 4.13 Mn |
| Mar 31, 2022 | 4.98 Mn |
| Dec 31, 2021 | 4.24 Mn |
| Sep 30, 2021 | 4.62 Mn |
| Jun 30, 2021 | 2.48 Mn |
| Mar 31, 2021 | 3.24 Mn |
| Dec 31, 2020 | 3.53 Mn |
| Sep 30, 2020 | 3.34 Mn |
| Jun 30, 2020 | 3.41 Mn |